5.53
price down icon8.29%   -0.50
after-market 시간 외 거래: 5.53
loading
전일 마감가:
$6.03
열려 있는:
$6
하루 거래량:
33,106
Relative Volume:
0.06
시가총액:
$9.52M
수익:
-
순이익/손실:
$-67.28M
주가수익비율:
-0.0584
EPS:
-94.66
순현금흐름:
$-9.80M
1주 성능:
-42.40%
1개월 성능:
+30.12%
6개월 성능:
+0.36%
1년 성능:
-46.47%
1일 변동 폭
Value
$5.5212
$6.03
1주일 범위
Value
$5.5212
$9.89
52주 변동 폭
Value
$2.098
$23.01

Portage Biotech Inc Stock (PRTG) Company Profile

Name
명칭
Portage Biotech Inc
Name
전화
-
Name
주소
-
Name
직원
7
Name
트위터
Name
다음 수익 날짜
2024-12-26
Name
최신 SEC 제출 서류
Name
PRTG's Discussions on Twitter

PRTG을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
PRTG
Portage Biotech Inc
5.53 9.52M 0 -67.28M -9.80M -94.66
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 125.40B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 65.79B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 35.18B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 32.67B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 26.46B 3.81B -644.79M -669.77M -6.24

Portage Biotech Inc Stock (PRTG) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2022-07-18 재개 Oppenheimer Outperform
2022-03-07 개시 H.C. Wainwright Buy
2021-09-21 개시 Oppenheimer Outperform
2021-09-02 개시 B. Riley Securities Buy
2021-08-19 개시 Cantor Fitzgerald Overweight

Portage Biotech Inc 주식(PRTG)의 최신 뉴스

pulisher
Apr 01, 2025

Small Cap Stocks To Add to Your WatchlistMarch 29th - MarketBeat

Apr 01, 2025
pulisher
Mar 31, 2025

Portage Biotech’s After-Hours Surge On Preclinical Tumor Trial Data Sends Retail Optimism Sky-High - Asianet Newsable

Mar 31, 2025
pulisher
Mar 30, 2025

Portage Biotech Insider Buyers See Boost After Market Cap Rose US$9.0m - simplywall.st

Mar 30, 2025
pulisher
Mar 30, 2025

Promising Biotech Stocks To Watch Now – March 28th - Defense World

Mar 30, 2025
pulisher
Mar 30, 2025

Portage Biotech (NASDAQ:PRTG) vs. Cytokinetics (NASDAQ:CYTK) Head-To-Head Survey - Defense World

Mar 30, 2025
pulisher
Mar 28, 2025

Biotech Firms Celebrate Gains With Promising Trials And Partnerships - Finimize

Mar 28, 2025
pulisher
Mar 28, 2025

Why Is Portage Biotech Stock Skyrocketing Friday? - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

Dow Tumbles Over 500 Points; Abacus Global Management Shares Spike Higher - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

Nasdaq Down 100 Points; Federal Reserve's Favorite Inflation Gauge Increases More Than Expected - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

Pre-market Movers: PRTG, RNAZ, PTIX, LGMK... - RTTNews

Mar 28, 2025
pulisher
Mar 28, 2025

Portage Biotech (PRTG) Shares Skyrocket In Pre-Hour Trading - Stocks Telegraph

Mar 28, 2025
pulisher
Mar 28, 2025

Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

Portage Biotech Shares Jump Premarket After 'Promising' Preclinical Results in Mesothelioma - Marketscreener.com

Mar 28, 2025
pulisher
Mar 27, 2025

Portage Biotech presents preclinical data for PORT-7 - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Portage Biotech reports promising mesothelioma treatment data By Investing.com - Investing.com Australia

Mar 27, 2025
pulisher
Mar 27, 2025

Portage Reports 'Promising' Preclinical Results in Mesothelioma - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Portage Biotech Announces Promising Preclinical Results for PORT-7 in Mesothelioma - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Portage Biotech Reports Promising Preclinical Results In Mesothelioma Supporting First-In-Human Trial Of Port-7 - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

Portage Biotech reports promising mesothelioma treatment data - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Portage Biotech stock soars on promising preclinical data - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Portage Biotech stock soars on promising preclinical data By Investing.com - Investing.com Canada

Mar 27, 2025
pulisher
Mar 27, 2025

Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7 - The Manila Times

Mar 27, 2025
pulisher
Mar 27, 2025

Game-Changing Mesothelioma Treatment: New Drug Achieves 90% Tumor Reduction in Latest Study - Stock Titan

Mar 27, 2025
pulisher
Mar 13, 2025

Portage Biotech Inc. Announces New Director Compensation Plan and Stock Option Grants - TipRanks

Mar 13, 2025
pulisher
Mar 12, 2025

Portage Biotech Resumes Patient Enrollment In Final Cohort Of Dose Escalation Stage For PORT-6 - Nasdaq

Mar 12, 2025
pulisher
Mar 12, 2025

Portage Biotech resumes enrollment in final group of its early-stage study for its cancer treatments - Marketscreener.com

Mar 12, 2025
pulisher
Mar 12, 2025

Portage Biotech Resumes Key Trial Enrollment, Advances Innovative Immunotherapy Approach - TipRanks

Mar 12, 2025
pulisher
Mar 12, 2025

Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial - The Manila Times

Mar 12, 2025
pulisher
Mar 12, 2025

Major Milestone: Portage Biotech's Novel Cancer Drug Enters Final Trial Phase - StockTitan

Mar 12, 2025
pulisher
Feb 28, 2025

Portage Biotech Stock More Than Doubles On Immunova Deal Potential: Retail Sees Big Opportunity - MSN

Feb 28, 2025
pulisher
Feb 25, 2025

Portage Biotech Announces Voluntary Delisting from the Canadian Securities Exchange - Newsfile

Feb 25, 2025
pulisher
Feb 16, 2025

Portage Biotech granted Nasdaq compliance extension By Investing.com - Investing.com Nigeria

Feb 16, 2025
pulisher
Feb 14, 2025

Portage Biotech receives extension from Nasdaq to attain listing compliance - MSN

Feb 14, 2025
pulisher
Feb 13, 2025

Portage Biotech granted Nasdaq compliance extension - MSN

Feb 13, 2025
pulisher
Feb 13, 2025

Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements - The Manila Times

Feb 13, 2025
pulisher
Feb 12, 2025

Portage Biotech Granted Nasdaq Compliance Extension - TipRanks

Feb 12, 2025
pulisher
Feb 12, 2025

Portage Biotech, Inc. Receives Extension to Regain Nasdaq Compliance Following Acceptance of Compliance Plan - Nasdaq

Feb 12, 2025
pulisher
Feb 12, 2025

Nasdaq Grants Portage Biotech Critical 18-Month Lifeline to Secure Exchange Status - StockTitan

Feb 12, 2025
pulisher
Feb 10, 2025

Hepatocellular Carcinoma Pipeline 2024: Latest FDA Approvals, - openPR

Feb 10, 2025
pulisher
Feb 04, 2025

What is the investor’s view on Portage Biotech Inc (PRTG)? - US Post News

Feb 04, 2025
pulisher
Feb 03, 2025

Pre-Market Surge: Portage Biotech (PRTG) Sees Upward Movement - Stocks Telegraph

Feb 03, 2025
pulisher
Jan 31, 2025

Portage Biotech Announces Completion of $2.15 Million Private Financing - The Manila Times

Jan 31, 2025
pulisher
Jan 30, 2025

Portage Biotech Secures $2.15 Million in Private Financing - TipRanks

Jan 30, 2025
pulisher
Jan 30, 2025

Portage Biotech, Inc. Completes $2.15 Million Private Placement to Support Corporate Growth - Nasdaq

Jan 30, 2025
pulisher
Jan 30, 2025

Insider Confidence: Portage Directors Invest $2.15M in Strategic Private Placement - StockTitan

Jan 30, 2025
pulisher
Jan 11, 2025

Portage Biotech (NASDAQ:PRTG) Stock Price Down 7.2% – Here’s What Happened - Defense World

Jan 11, 2025
pulisher
Jan 07, 2025

Portage Biotech Inc. Appoints Peter Molloy as CEO of Subsidiary, Cyncado Therapeutics, Inc - Marketscreener.com

Jan 07, 2025
pulisher
Jan 06, 2025

Portage Biotech Re-Launches Subsidiary as Cyncado Therapeutics with New CEO - TipRanks

Jan 06, 2025

Portage Biotech Inc (PRTG) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$60.26
price down icon 10.70%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
자본화:     |  볼륨(24시간):